Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1.97) by 73.1 percent. This is a 55.83 percent increase over losses of $(1.20) per share from the same period last year. The company reported quarterly sales of $19.95 million which beat the analyst consensus estimate of $14.89 million by 33.96 percent. This is a 21.59 percent increase over sales of $16.40 million the same period last year.